Dr. Nils Lonberg is Senior VP, Oncology Discovery Biology, at Bristol-Myers Squibb, where he leads drug discovery efforts for targeted oncology agents and immuno-oncology agents. Dr. Lonberg began his career leading the research group at GenPharm International that developed genetically engineered strains of mice with germline-configuration human immunoglobulin genes. In 1997, GenPharm was acquired by Medarex, which was acquired by Bristol-Myers Squibb in 2009. Beginning in 1998, the Medarex drug discovery group focused on antibody therapies that target and modulate immune attenuating pathways to activate immune responses to cancer cells. Ipilimumab, which gained regulatory approval in 2011, was the first drug to demonstrate a survival benefit for patients with metastatic melanoma in a randomized clinical trial. A second checkpoint blockade cancer therapeutic, nivolumab, was approved in 2014. Dr. Lonberg received his Ph.D. in Biochemistry and Molecular Biology from Harvard University in 1985, where he studied under Walter Gilbert.